MedTrace Logo

Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery

NCT00290355 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 182

Last updated 2020-01-02

Study results available
· View outcomes & findings →

Summary

Patients will receive injections of GSK 249553 vaccine . Appropriate tests will be performed to assess the safety of the treatment and its ability to induce an immune response.

Conditions

  • Lung Cancer, Non-Small Cell

Interventions

BIOLOGICAL

GSK 249553 vaccine

Intramuscular injection, 13 doses

BIOLOGICAL

Placebo

Intramuscular administration, 13 doses

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-05-28
Primary Completion
2011-07-19
Completion
2011-07-19

Countries

  • Belgium
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Italy
  • Latvia
  • Lithuania
  • Netherlands
  • Norway
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00290355 on ClinicalTrials.gov